0001137604-13-000004.txt : 20130710 0001137604-13-000004.hdr.sgml : 20130710 20130710153502 ACCESSION NUMBER: 0001137604-13-000004 CONFORMED SUBMISSION TYPE: PX14A6G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130710 DATE AS OF CHANGE: 20130710 EFFECTIVENESS DATE: 20130710 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MCKESSON CORP CENTRAL INDEX KEY: 0000927653 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 943207296 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: PX14A6G SEC ACT: 1934 Act SEC FILE NUMBER: 001-13252 FILM NUMBER: 13961866 BUSINESS ADDRESS: STREET 1: ONE POST ST STREET 2: MCKESSON PLAZA CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 4159838300 MAIL ADDRESS: STREET 1: ONE POST ST CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON HBOC INC DATE OF NAME CHANGE: 19990115 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON CORP DATE OF NAME CHANGE: 19950209 FORMER COMPANY: FORMER CONFORMED NAME: SP VENTURES INC DATE OF NAME CHANGE: 19940728 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AMALGAMATED BANK LONGVIEW FUNDS CENTRAL INDEX KEY: 0001137604 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: PX14A6G BUSINESS ADDRESS: STREET 1: 275 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 2122556200 MAIL ADDRESS: STREET 1: 275 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: AMALGAMATED BANK OF NEW YORK LONGVIEW COLLECTIVE INVESTMENT DATE OF NAME CHANGE: 20010403 PX14A6G 1 shltr.txt SHAREHOLDER LETTER U.S. Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION 1. Name of the Registrant: MCKESSON CORPORATION ___________________________________________________________________________ 2. Name of the person relying on exemption: AMALGAMATED BANK LONGVIEW FUNDS ___________________________________________________________________________ 3. Address of the person relying on exemption: 275 SEVENTH AVENUE, NEW YORK, NY 10001 ___________________________________________________________________________ 4. Written materials. Attach written materials required to be submitted pursuant to Rule 14a6(g)(1): (LOGO) AMALGAMATED BANK (LOGO) UAW RETIREE MEDICAL BENEFITS TRUST THIS IS NOT A PROXY SOLICITATION AND NO PROXY CARDS WILL BE ACCEPTED. Please execute and return your proxy card according to McKesson's instructions.
July 2013 Dear McKesson Shareholder: We urge you to vote "YES" on Item #10 ("Stockholder Proposal on Compensation Clawback Policy") at the upcoming Annual Meeting of McKesson (NYSE: MCK), to be held July 31, 2013. Item #10 is a non-binding, advisory proposal that encourages the board to strengthen the company' clawback policy and disclose when the clawback is applied to senior executives' incentive compensation. WHY IS A STRONG CLAWBACK POLICY IMPORTANT? We believe clawbacks underscore "pay-for-performance" for executives in the following ways: - PROMOTE ALIGNMENT BETWEEN PAY AND PERFORMANCE by adjusting incentive compensation when pay is later determined to have been based on the wrong numbers or misconduct. - FOSTER A CORPORATE CULTURE OF COMPLIANCE AND DISCOURAGE FUTURE COMPLIANCE VIOLATIONS by establishing and communicating concrete consequences for misconduct. - INCREASE ACCOUNTABILITY TO SHAREHOLDERS AND OTHER STAKEHOLDERS by informing them about the application of the clawback policy. WHY IS MCKESSON'S CURRENT POLICY INADEQUATE? The company's current policy is weak in three ways: - IT IS ONLY TRIGGERED IF EMBEZZLEMENT OR FRAUD MEETS AN UNDEFINED "MATERIALITY" THRESHOLD: We believe that all embezzlement, fraud, or theft is problematic and costly to shareholders, regardless of its materiality. We believe the Board should have a policy in place to review incentive compensation and be empowered to recoup unearned pay, regardless of an undefined "materiality." - IT IS ONLY TRIGGERED IN THE EVENT OF "INTENTIONAL" MISCONDUCT IN FINANCIAL REPORTING: We do not think it is necessary for the Board to assess whether or not financial errors were "intentional." If the numbers upon which incentive pay is calculated are incorrect, the Board should be in a position to adjust pay accordingly. - THERE IS NO DISCLOSURE OF ANY CLAWBACK ENFORCEMENT DESPITE MCKESSON'S CHRONIC LEGAL AND REGULATORY SETTLEMENTS: If executives receive incentive pay despite engaging in "misconduct," intentional or otherwise, we believe that the Board should report whether and how it has applied a clawback policy. IS THE REQUEST PRACTICAL? Yes. Item #10 recommends a general policy and leaves the specific details of its implementation to the Board of Directors. Other companies have policies to make disclosures of the sort being urged here, such as Capital One and Encore Capital Group./1/ HAVE OTHER COMPANIES IN THE INDUSTRY IMPLEMENTED SIMILAR POLICIES: Yes. Numerous pharmaceutical distribution and health care-related companies, such as Johnson & Johnson, Boston Scientific Corporation, Quest Diagnostics, HealthWays, Merck & Company, Eli Lilly & Company, Amgen Corporation, Bristol-Myers Squibb, and Pfizer have more expansive clawback provisions./2/ HOW HAS THE COMPANY RESPONDED TO THE SHAREHOLDER PROPOSAL? The shareholder proponents requested a discussion with the company on the content of the proposal, but to date have not received any response. We urge you to vote FOR Item #10. Sincerely, Scott Zdrazil Meredith Miller First Vice President- Chief Corporate Governance Officer Director of Corporate Governance UAW Retiree Medical Benefits Trust Amalgamated Bank LongView Funds (734) 887-4964 (212) 895-4923 mamiller@rhac.com scottzdrazil@amalgamatedbank.com THIS IS NOT A PROXY SOLICITATION AND NO PROXY CARDS WILL BE ACCEPTED. Please execute and return your proxy card according to McKesson's instructions.
/1/ Liz Moyer. "Banks Bow to New York On Clawbacks." Wall Street Journal 13 March 2013. http://online.wsj.com/article/SB1000142412788732407770457835879184 0450814.html; Capital One 2013 Proxy Statement, http://www.sec.gov/Archives/ edgar/data/927628/000120677413001099/capitalone_def14a.htm; Encore Capital Group 2013 Proxy Statement,http://www.sec.gov/Archives/edgar/data/1084961/ 000119312513175622/d487991ddef14a.htm /2/ Joann S. Lublin and Jonathan D. Rockoff. "Drug Companies Expand Powers to Recoup Pay." Wall Street Journal 3 April 2013. http://online.wsj.com/article/ SB10001424127887323646604578400912618817612.html